对于非霍奇金淋巴瘤和多发性骨髓瘤患者在接受CAR T疗法后接种COVID-19疫苗作出回应。
Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma.
发表日期：2023 Mar 07
作者：
Julia E Wiedmeier-Nutor, Madiha Iqbal, Allison C Rosenthal, Evandro D Bezerra, Juan Esteban Garcia-Robledo, Radhika Bansal, Patrick B Johnston, Matthew Hathcock, Jeremy T Larsen, P Leif Bergsagel, Yucai Wang, Craig B Reeder, Jose F Leis, Rafael Fonseca, Jeanne M Palmer, Brianna J Gysbers, Raphael Mwangi, Rahma M Warsame, Taxiarchis Kourelis, Suzanne R Hayman, David Dingli, Prashant Kapoor, Shaji K Kumar, Urshila Durani, Jose C Villasboas, Jonas Paludo, N Nora Bennani, Grzegorz Nowakowski, Stephen M Ansell, Januario E Castro, Mohamed A Kharfan-Dabaja, Yi Lin, Paschalis Vergidis, Hemant S Murthy, Javier Munoz
来源：
Cellular & Molecular Immunology
摘要：
COVID-19对患有癌症的人造成不良影响。多项研究发现，血液恶性肿瘤患者的血清转归率与无癌症患者相比，不尽如人意。非何杰金淋巴瘤（NHL）和多发性骨髓瘤（MM）患者的免疫能力受到损害，除了受处方免疫抑制疗法的影响外，还受到细胞和体液免疫能力的影响。人工嵌合抗原受体T细胞（CAR T）疗法现在广泛用于NHL和MM，但对这些患者在COVID-19疫苗接种后的血清转归率知之甚少。我们对NHL和MM CAR T疗法接受者在COVID-19疫苗接种后进行了SARS-CoV-2刺突结合IgG抗体水平的评估。在104种CAR T输注中，19名患者在CAR T后发生已知的COVID-19感染。我们检测了17名接受CAR T治疗的患者在COVID-19疫苗接种后的抗体刺突滴度，只有29%（n = 5）能够产生临床相关的抗体反应（> 250 IU / mL）。Copyright ©2023 Elsevier Inc. All rights reserved.
COVID-19 adversely affects individuals with cancer. Several studies have found that seroconversion rates among patients with hematologic malignancies are suboptimal when compared to patients without cancer. Patients with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM) are immunocompromised due to impaired humoral and cellular immunity in addition to prescribed immunosuppressive therapy. Chimeric antigen receptor T-cell (CAR T) therapy is now widely used for NHL and MM, but little is known about seroconversion rates after COVID-19 vaccination among these populations. We evaluated SARS-CoV-2 spike-binding IgG antibody levels following COVID-19 vaccination among NHL and MM CAR T therapy recipients. Out of 104 CAR T infusions, 19 patients developed known COVID-19 infection post-CAR T. We tested 17 patients that received CAR T for antibody spike titers post COVID-19 vaccination, only 29 % (n = 5) were able to mount a clinically relevant antibody response (>250 IU/mL).Copyright © 2023 Elsevier Inc. All rights reserved.